"Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904." by Robert L. Coleman

Selected Works of Jed Delmore, MD, FACOG, FACS

Article

Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904.

Journal of Clinical Oncology (2012)

Robert L. Coleman, University of Texas MD Anderson Cancer Center
James Moon, Southwest Oncology Group Statistical Center, Seattle, WA
Anil Sood, University of Texas MD Anderson Cancer Center
Donna Branham, University of Texas MD Anderson Cancer Center
James Edwin Delmore, Wichita CCOP/Associates In Women's Health, Wichita, KS
Albert J. Bonebrake, Cancer Research for the Ozarks-Cox Health, Springfield, MO
Garnet L Anderson, Fred Hutchinson Cancer Research Center
David Samuel Alberts, Arizona Cancer Center, Tucson, AZ
Maurie Markman, Cancer Treatment Centers of America

Link

Disciplines

Publication Date

May 20, 2012

DOI

10.1200/JCO.2012.30.15_SUPPL.5015

Citation Information

Robert L. Coleman, James Moon, Anil Sood, Donna Branham, et al.. "Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904." Journal of Clinical Oncology Vol. 30 (2012) p. 5015 - 5015
Available at: http://works.bepress.com/james-delmore/5/